Proposal of a new limited sampling strategy to predict CYP3A activity using a partial AUC of midazolam

No abstract is available for this paper.

• Publication year

  2010

• Venue

  European Journal of Clinical Pharmacology

• Publication date

  2010-08-03

• Fields of study

  Medicine, Computer Science

• Identifiers
  DOI 10.1007/s00228-010-0878-2PMID 20680253
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of Simultaneous Induction and Inhibition of CYP3A by St John's Wort and Ritonavir on CYP3A Activity

  2010cited by this paper
• Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase.

  2009cited by this paper
• Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping.

  2008cited by this paper
• Limitations of Using a Single Postdose Midazolam Concentration to Predict CYP3A‐Mediated Drug Interactions

  2008cited by this paper
• New findings in studies of cytochromes P450

  2008cited by this paper
• Single‐point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam

  2005cited by this paper
• A sensitive, rapid and specific determination of midazolam in human plasma and saliva by liquid chromatography/electrospray mass spectrometry.

  2004cited by this paper
• Single Plasma Concentrations of 1′‐Hydroxymidazolam or the Ratio of 1′‐Hydroxymidazolam: Midazolam Do Not Predict Midazolam Clearance in Healthy Subjects

  2002cited by this paper
• Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes.

  2000cited by this paper
• Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism

  1996cited by this paper
• A limited sampling strategy for cyclophosphamide pharmacokinetics.

  1989cited by this paper
• Limited sampling model for vinblastine pharmacokinetics.

  1987cited by this paper

• Effect of the frequently used antiepileptic drugs carbamazepine, gabapentin, and pregabalin on the pharmacokinetics of edoxaban and other oral factor xa inhibitors in healthy volunteers

  2025cites this paper
• In vivo effects of bempedoic acid on microdosed CYP probe drugs

  2025cites this paper
• Limited Sampling Strategy of Rosuvastatin Single-Time-point Concentrations Accurately Estimate Exposure and Constitutive Transporter Activities in Healthy Adults.

  2025cites this paper
• Effect of Tacrolimus Formulation (Prolonged‐Release vs Immediate‐Release) on Its Susceptibility to Drug‐Drug Interactions with St. John's Wort

  2024cites this paper
• Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers

  2024cites this paper
• Evaluation of Hydroxychloroquine as a Perpetrator on Cytochrome P450 (CYP) 3A and CYP2D6 Activity with Microdosed Probe Drugs in Healthy Volunteers

  2023cites this paper
• Limitations of fexofenadine limited sampling strategy using plasma concentrations and partial area under the concentration-time curve to estimate transporter activity in healthy adults

  2023influential citation
• Evaluation of the drug-drug interaction potential of the novel hepatitis B and D virus entry inhibitor bulevirtide at OATP1B in healthy volunteers

  2023cites this paper
• Influence of a Short Course of Ritonavir Used as Booster in Antiviral Therapies Against SARS-CoV-2 on the Exposure of Atorvastatin and Rosuvastatin

  2023influential citation
• Time course of CYP3A activity during and after metamizole (dipyrone) in healthy volunteers

  2023cites this paper
• Effect of Clarithromycin, a Strong CYP3A and P-glycoprotein Inhibitor, on the Pharmacokinetics of Edoxaban in Healthy Volunteers and the Evaluation of the Drug Interaction with Other Oral Factor Xa Inhibitors by a Microdose Cocktail Approach

  2023influential citation
• Physiologically‐based pharmacokinetic modeling to predict CYP3A4‐mediated drug‐drug interactions of finerenone

  2021cites this paper
• Perpetrator Characteristics of Azole Antifungal Drugs on Three Oral Factor Xa Inhibitors Administered as a Microdosed Cocktail

  2021cites this paper
• Midazolam microdosing applied in early clinical development for drug–drug interaction assessment

  2020cites this paper
• No Alteration Of Cyp3a4 Activity After Major Hepatectomy In The Early Postoperative Period - A Prospective Before-After Study.

  2020cites this paper
• Validation of a 3-h Sampling Interval to Assess Variability in Cytochrome P450 3A Phenotype and the Impact of Induction and Mechanism-Based Inhibition Using Midazolam as a Probe Substrate

  2019cites this paper
• Decreased Cytochrome P450 3A activity in palliative patients with haematological diseases: Potential impact on supportive drug therapies

  2019cites this paper
• Alteration of drug-metabolizing enzyme activity in palliative care patients: Microdosed assessment of cytochrome P450 3A

  2019cites this paper
• Prolonged‐Release Tacrolimus Is Less Susceptible to Interaction With the Strong CYP3A Inhibitor Voriconazole in Healthy Volunteers

  2019cites this paper
• Minor contribution of cytochrome P450 3A activity on fentanyl exposure in palliative care cancer patients

  2019cites this paper
• Midazolam Single Time Point Concentrations to Estimate Exposure and Cytochrome P450 (CYP) 3A Constitutive Activity Utilizing Limited Sampling Strategy With a Population Pharmacokinetic Approach

  2018cites this paper
• Rivaroxaban and macitentan can be coadministered without dose adjustment but the combination of rivaroxaban and St John's wort should be avoided

  2018cites this paper
• Towards better dose individualisation: metabolic phenotyping to predict cabazitaxel pharmacokinetics in men with prostate cancer

  2017cites this paper
• Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy

  2015cites this paper
• Pharmacokinetic interaction of intravenous fentanyl with ketoconazole

  2015cites this paper
• Limited Sampling Strategy of Partial Area Under the Concentration–Time Curves to Estimate Midazolam Systemic Clearance for Cytochrome P450 3A Phenotyping

  2015influential citation
• Normal CYP3A activity during arsenic trioxide therapy

  2014cites this paper
• Systemic exposure of topical erythromycin in comparison to oral administration and the effect on cytochrome P450 3A4 activity.

  2014cites this paper
• Reduced exposure variability of the CYP3A substrate simvastatin by dose individualization to CYP3A activity

  2013cites this paper
• Concentration effect relationship of CYP3A inhibition by ritonavir in humans

  2013cites this paper
• Evaluation of partial area under the concentration time curve to estimate midazolam apparent oral clearance for cytochrome P450 3A phenotyping

  2013influential citation
• A Nanogram Dose of the CYP3A Probe Substrate Midazolam to Evaluate Drug Interactions

  2013cites this paper
• Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity

  2013cites this paper
• Evaluation of limited sampling models for prediction of oral midazolam AUC for CYP3A phenotyping and drug interaction studies

  2012cites this paper
• Determining the Time Course of CYP3A Inhibition by Potent Reversible and Irreversible CYP3A Inhibitors Using A Limited Sampling Strategy

  2011cites this paper